Overview on interferon in the mucosa immune response of pig mucosal immunity
LIU Lirong1,2, HOU Lidan3, WANG Meng2, LIU Wenjun1,2, LI Jing1,2
1. CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China;
2. Savaid Medical School, University of Chinese Academy of Sciences, Beijing 100049, China;
3. Department of viral biologics, China Institute of Veterinary Drug Control, Beijing 100081, China
Abstract：The animal mucosal immune system serves as the material basis of the immune response, and plays an important role. The vaccine is induced by the mucosal antibody derived from the mucosal immune system, followed by the activated systemic immune response. The interferon acts as a potential mucosal immune adjuvant involved in many biological functions, such as antivirus and immune regulation. This paper reviews the correlation between the mucosal innate immunity and the porcine interferon, focusing on the immunomodulatory roles of the mucosal immune system, the porcine interferon signaling pathway and the immunologic adjuvant, to provide a reference for the development of the porcine interferon as a mucosal immune adjuvant.
刘丽蓉, 侯力丹, 王萌, 刘文军, 李晶. 干扰素在猪黏膜免疫应答中的研究进展[J]. 科技导报, 2018, 36(21): 109-115.
LIU Lirong, HOU Lidan, WANG Meng, LIU Wenjun, LI Jing. Overview on interferon in the mucosa immune response of pig mucosal immunity. Science & Technology Review, 2018, 36(21): 109-115.
[1] Fujimoto K, Karuppuchamy T, Takemura N, et al. A new subset of CD103+CD8alpha+ dendritic cells in the small intestine expresses TLR3, TLR7, and TLR9 and induces Th1 response and CTL activity[J]. Journal of Immunology, 2011, 186(11):6287-6295.
[2] Liu C H, Liu H, Ge B. Innate immunity in tuberculosis:host defense vs pathogen evasion[J]. Cellular & Molecular Immunology, 2017, 14(12):963-975.
[3] Le Bon A, Schiavoni G, D'Agostino G, et al. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo[J]. Immunity, 2001, 14(4):461-470.
[4] Doehle B P, Hladik F, McNevin J P, et al. Human immunodeficiency virus type 1 mediates global disruption of innate antiviral signaling and immune defenses within infected cells[J]. Journal of Virology, 2009, 83(20):10395-10405.
[5] Koerner I, Kochs G, Kalinke U, et al. Protective role of beta interferon in host defense against influenza A virus[J]. Journal of Virology, 2007, 81(4):2025-2030.
[6] Yoo J K, Baker D P, Fish E N. Interferon-β modulates type 1 immunity during influenza virus infection[J]. Antiviral Research, 2010, 88(1):64-71.
[7] Parker D, Martin F J, Soong G, et al. Streptococcus pneumoniae DNA initiates type I interferon signaling in the respiratory tract[J]. MBio, 2011, 2(3):e00016-11.
[8] Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis[J]. Cell, 2004, 118(2):229-241.
[9] McFarland A P, Savan R, Wagage S, et al. Localized delivery of interferon-beta by Lactobacillus exacerbates experimental colitis[J]. PLoS One, 2011, 6(2):e16967.
[10] Weiss G, Rasmussen S, Zeuthen L H, et al. Lactobacillus acidophilus induces virus immune defence genes in murine dendritic cells by a Toll-like receptor-2-dependent mechanism[J]. Immunology, 2010, 131(2):268-281.
[11] Mirpuri J, Brazil J C, Berardinelli A J, et al. Commensal Escherichia coli reduces epithelial apoptosis through IFN-alphaAmediated induction of guanylate binding protein-1 in human and murine models of developing intestine[J]. Journal of Immunology, 2010, 184(12):7186-7195.
[12] Svensson A, Bellner L, Magnusson M, et al. Role of IFN-alpha/beta signaling in the prevention of genital herpes virus type 2 infection[J]. Journal of Reproductive Immunology, 2007, 74(1-2):114-123.
[13] Härle P, Noisakran S, Carr D J. The application of a plasmid DNA encoding IFN-alpha 1 postinfection enhances cumulative survival of herpes simplex virus type 2 vaginally infected mice[J]. Journal of Immunology, 2001, 166(3):1803-1812.
[14] Austin B A, James C M, Härle P, et al. Direct application of plasmid DNA containing type I interferon transgenes to vaginal mucosa inhibits HSV-2 mediated mortality[J]. Biological Procedures Online, 2006, 8:55-62.
[15] Diaz-San Segundo F, Moraes M P, de Los Santos T, et al. Interferon-induced protection against foot-and-mouth disease virus infection correlates with enhanced tissue-specific innate immune cell infiltration and interferon-stimulated gene expression[J]. Journal of Virology, 2010, 84(4):2063-2077.
[16] Yao Q, Qian P, Cao Y, et al. Synergistic inhibition of pseudorabies virus replication by porcine alpha/beta interferon and gamma interferon in vitro[J]. European Cytokine Network, 2007, 18(2):71-77.
[17] Kim S M, Park J H, Lee K N, et al. Robust Protection against Highly Virulent Foot-and-Mouth Disease Virus in Swine by Combination Treatment with Recombinant Adenoviruses Expressing Porcine Alpha and Gamma Interferons and Multiple Small Interfering RNAs[J]. Journal of Virology, 2015, 89(16):8267-8279.
[18] Baumann A, McCullough K C, Summerfield A. Porcine circovirus type 2 stimulates plasmacytoid dendritic cells in the presence of IFN-gamma[J]. Veterinary Immunology and Immunopathology, 2013, 156(3-4):223-228.
[19] Vandenbroeck K, Nauwynck H, Vanderpooten A, et al. Recombinant porcine IFN-gamma potentiates the secondary IgG and IgA responses to an inactivated suid herpesvirus-1 vaccine and reduces postchallenge weight loss and fever in pigs[J]. Journal of Interferon and Cytokine Research, 1998, 18(9):739-744.
[20] Li L, Fu F, Xue M, et al. IFN-lambda preferably inhibits PEDV infection of porcine intestinal epithelial cells compared with IFN-alpha[J]. Antiviral Research, 2017,140:76-82.
[21] Du L, Li B, He K, et al. Construction and immunogenicity of DNA vaccines encoding fusion protein of porcine IFN-λ 1 and GP5 gene of porcine reproductive and respiratory syndrome virus[J]. Biomed Research International, 2013, 2013:318698.
[22] Schoggins J W, Wilson S J, Panis M, et al. A diverse range of gene products are effectors of the type I interferon antiviral response[J]. Nature, 2011, 472(7344):481-485.
[23] Biron CA. Interferons alpha and beta as immune regulators-a new look[J]. Immunity, 2001, 14(6):661-664.
[24] Santini S M, Lapenta C, Logozzi M, et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice[J]. Journal of Experimental Medicine, 2000, 191(10):1777-1788.
[25] McBride S, Hoebe K, Georgel P, et al. Cell-associated double-stranded RNA enhances antitumor activity through the production of type I IFN[J]. Journal of Immunology, 2006, 177(9):6122-6128.
[26] Braun D, Caramalho I, Demengeot J. IFN-alpha/beta enhances BCR-dependent B cell responses[J]. International Immunology, 2002, 14(4):411-419.
[27] Mangan N E, Fung K Y. Type I interferons in regulation of mucosal immunity[J]. Immunology and Cell Biology, 2012, 90(5):510-519.
[28] Mamber S W, Lins J, Gurel V, et al. Low-dose oral interferon modulates expression of inflammatory and autoimmune genes in cattle[J]. Veterinary Immunology and Immunopathology, 2016, 172:64-71.
[29] Beaurepaire C, Smyth D, McKay D M. Interferon-gamma regulation of intestinal epithelial permeability[J]. Journal of Interferon and Cytokine Research, 2009, 29(3):133-144.
[30] Kotenko S V, Gallagher G, Baurin V V, et al. IFN-lambdas mediate antiviral protection through a distinct class Ⅱ cytokine receptor complex[J]. Nature Immunology, 2003, 4(1):583-590.
[31] Schindler C, Plumlee C. Inteferons pen the JAK-STAT pathway[J]. Seminars in Cell & Developmental Biology, 2008, 19(4):311-318.
[32] Samarajiwa S A, Forster S, Auchettl K, et al. INTERFEROME:the database of interferon regulated genes[J]. Nucleic Acids Research, 2009, 37(Database issue):D852-857.
[33] Sommereyns C, Paul S, Staeheli P, et al. IFN-lambda (IFNlambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo[J]. PLoS Pathogens, 2008, 4(3):e1000017.
[34] Zanoni I, Granucci F, Broggi A. Interferon (IFN)-lambda Takes the Helm:Immunomodulatory Roles of Type Ⅲ IFNs[J]. Frontiers in Immunology, 2017, 8:1661.
[35] Baldridge M T, Lee S, Brown J J, et al. Expression of Ifnlr1 on Intestinal Epithelial Cells Is Critical to the Antiviral Effects of Interferon Lambda against Norovirus and Reovirus[J]. Journal of Virology, 2017, pii:e02079-16.
[36] Zhang Q, Ke H, Blikslager A, et al. Type Ⅲ Interferon Restriction by Porcine Epidemic Diarrhea Virus and the Role of Viral Protein nsp1 in IRF1 Signaling[J]. Journal of Virology, 2018, pii:e01677-17.
[37] Blazek K, Eames H L, Weiss M, et al. IFN-λ resolves inflammation via suppression of neutrophil infiltration and IL-1β production[J]. journal of experimental medicine, 2015, 212(6):845-853.
[38] Chrysanthopoulou A, Kambas K, Stakos D, et al. Interferon lambda1/IL-29 and inorganic polyphosphate are novel regulators of neutrophil-driven thromboinflammation[J]. Journal of Pathology, 2017, 243(1):111-122.
[39] Galani I E, Triantafyllia V, Eleminiadou E E, et al. Interferonlambda Mediates Non-redundant Front-Line Antiviral Protection against Influenza Virus Infection without Compromising Host Fitness[J]. Immunity, 2017, 46(5):875-890.
[40] Broggi A, Tan Y, Granucci F, et al. IFN-λ suppresses intestinal inflammation by non-translational regulation of neutrophil function[J]. Nature Immunology, 2017, 18(10):1084-1093.
[41] Wang Y, Li T, Chen Y, et al. Involvement of NK Cells in IL-28B-Mediated Immunity against Influenza Virus Infection[J]. Journal of Immunology, 2017, 199(3):1012-1020.
[42] Bracci L, Canini I, Puzelli S, et al. Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level[J]. Vaccine, 2005, 23(23):p. 2994-3004.
[43] Cao M, Sasaki O, Yamada A, et al. Enhancement of the protective effect of inactivated influenza virus vaccine by cytokines[J]. Vaccine, 1992, 10(4):238-242.
[44] Holmgren J, Czerkinsky C, Eriksson K, et al. Mucosal immunisation and adjuvants:a brief overview of recent advances and challenges[J]. Vaccine, 2003, 21 Suppl 2:S89-95.
[45] Mutsch M, Zhou W, Rhodes P, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland[J]. New England Journal of Medicine, 2004, 350(9):896-903.
2018, Vol. 36 
